# ExoNeuglia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exoneuglia

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Latest round: Angel (Dec 8, 2022)
- Investors on record: 1

## About

Based in Suzhou, China, and founded in 2022, ExoNeuglia is a biotechnology company dedicated to the development of speciality neurological-related stem cell drugs. The founder and CEO of the company, Ying Guo, graduated from the University of Barcelona and has been engaged in the research of neural demyelinating disease drugs and stem cell therapy for 11 years. Co-founder Wenbin Deng is the dean of Shenzhen School of Pharmacy, Sun Yat-sen University. In July 2024, ExoNeuglia closed a round of strategic investment. The company mainly provides cell and exosome therapy services for neurological diseases. It uses cell reprogramming and induced differentiation technology to develop a technology platform for OPC (Oligodendrocyte Precursor Cells) to treat neurological diseases. ExoNeuglia also focuses on iPSC (induced pluripotent stem cells) cell therapy for neural demyelinating diseases and is dedicated to the development of speciality neurological-related stem cell drugs. The drug is suitable for patients with myelin loss in the nervous system and diseases such as spinal cord injury, multiple sclerosis, and neuromyelitis optical. The company generates revenue by developing specialized neural-related stem cell drugs and providing cell and exosome treatment services for neurological diseases. The company will use the strategic investment funding to accelerate investigator-initiated clinical trials (IITs) and investigational new drug submissions (INDs) in the pipeline for demyelinating diseases and other areas. In August 2025, ExoNeuglia raised series A+ funding from new investor Xiahui Tiantong Technology Investment.

## Funding rounds

- Angel, Dec 8, 2022 — Redhill Capital

## Investors

- Redhill Capital (https://capitalatlas.ai/funds/redhill-capital) — Angel